Tekla Life Sciences Investors (NYSE:HQL) — Market Cap & Net Worth
Market Cap & Net Worth: Tekla Life Sciences Investors (HQL)
Tekla Life Sciences Investors (NYSE:HQL) has a market capitalization of $502.59 Million ($502.59 Million) as of May 4, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #12509 globally and #2931 in its home market, demonstrating a 0.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tekla Life Sciences Investors's stock price $17.55 by its total outstanding shares 29598692 (29.60 Million). Analyse HQL cash flow metrics to see how efficiently the company converts income to cash.
Tekla Life Sciences Investors Market Cap History: 2015 to 2026
Tekla Life Sciences Investors's market capitalization history from 2015 to 2026. Data shows growth from $299.11 Million to $519.46 Million (5.26% CAGR).
Tekla Life Sciences Investors Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tekla Life Sciences Investors's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.75x
Tekla Life Sciences Investors's market cap is 5.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.80x
Tekla Life Sciences Investors's market cap is 5.80 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $240.91 Million | $6.29 Million | -$11.91 Million | 38.29x | N/A |
| 2017 | $302.37 Million | $69.81 Million | $68.56 Million | 4.33x | 4.41x |
| 2018 | $253.44 Million | $1.99 Million | $28.66 Million | 127.62x | 8.84x |
| 2019 | $318.15 Million | $-69.34 Million | -$70.48 Million | -4.59x | N/A |
| 2020 | $393.62 Million | $124.08 Million | $123.05 Million | 3.17x | 3.20x |
| 2021 | $415.36 Million | $65.69 Million | $64.53 Million | 6.32x | 6.44x |
| 2022 | $335.57 Million | $-103.25 Million | -$104.60 Million | -3.25x | N/A |
| 2023 | $349.76 Million | $23.52 Million | $22.35 Million | 14.87x | 15.65x |
| 2024 | $388.33 Million | $86.69 Million | $85.30 Million | 4.48x | 4.55x |
| 2025 | $496.67 Million | $86.39 Million | $85.59 Million | 5.75x | 5.80x |
Competitor Companies of HQL by Market Capitalization
Companies near Tekla Life Sciences Investors in the global market cap rankings as of May 4, 2026.
Key companies related to Tekla Life Sciences Investors by market ranking:
- BlackRock Inc (NYSE:BLK): Ranked #140 globally with a market cap of $155.79 Billion USD.
- Brookfield Corporation (TO:BN): Ranked #245 globally with a market cap of $99.82 Billion USD ( CA$137.99 Billion CAD).
- Blackstone Group Inc (NYSE:BX): Ranked #267 globally with a market cap of $94.60 Billion USD.
- KKR & Co LP (NYSE:KKR): Ranked #280 globally with a market cap of $92.43 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #140 | BlackRock Inc | NYSE:BLK | $155.79 Billion | $1061.68 |
| #245 | Brookfield Corporation | TO:BN | $99.82 Billion | CA$61.48 |
| #267 | Blackstone Group Inc | NYSE:BX | $94.60 Billion | $126.35 |
| #280 | KKR & Co LP | NYSE:KKR | $92.43 Billion | $103.68 |
Tekla Life Sciences Investors Historical Marketcap From 2015 to 2026
Between 2015 and today, Tekla Life Sciences Investors's market cap moved from $299.11 Million to $ 519.46 Million, with a yearly change of 5.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $519.46 Million | +4.59% |
| 2025 | $496.67 Million | +27.90% |
| 2024 | $388.33 Million | +11.03% |
| 2023 | $349.76 Million | +4.23% |
| 2022 | $335.57 Million | -19.21% |
| 2021 | $415.36 Million | +5.52% |
| 2020 | $393.62 Million | +23.72% |
| 2019 | $318.15 Million | +25.53% |
| 2018 | $253.44 Million | -16.18% |
| 2017 | $302.37 Million | +25.51% |
| 2016 | $240.91 Million | -19.46% |
| 2015 | $299.11 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Tekla Life Sciences Investors was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $502.59 Million USD |
| MoneyControl | $502.59 Million USD |
| MarketWatch | $502.59 Million USD |
| marketcap.company | $502.59 Million USD |
| Reuters | $502.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more